source
- GSK receives FDA approval for hepatitis B therapy that expands functional cure ratesGSK announced that the U.S. Food and Drug Administration has granted approval for its hepatitis B drug. The agency said the treatment can achieve functional cures in a larger proportion of patient…
- FDA approves GSK‑Ionis hepatitis B functional cure, Hibsago, targeting undetectable virus after six monthsThe FDA has approved bepirovirsen, an antisense oligonucleotide from GSK and Ionis, for chronic hepatitis B infection. It will be sold under the brand name Hibsago. The therapy is described as a f…